Palisade Bio’s PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study

May 1, 2024

DENVER, Colo., May 01, 2024 (247marketnews.com)- Palisade Bio, Inc. (Nasdaq:PALI) stated that it completed its analysis to determine the effects of bioactivated PALI-2108, Palisade’s orally administered, locally acting, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug, on TNF-α production in a whole blood (WB) assay.

“These important data bolster our confidence in the robust anti-inflammatory potential of PALI-2108 in the management of UC,” stated Dr. Mitch Jones, CMO of Palisade Bio. “The superior efficacy of PALI-2108, as demonstrated by its lower half-maximal inhibitory concentration (or IC50) compared to the approved PDE4 inhibitor apremilast, underscores its potential as a next-generation therapeutic option for patients with inflammatory bowel disease.”

Palisade is on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before the end of 2024.

Palisade Bio’s CEO, JD Finley, added “Our team’s exceptional operational execution is driving the clinical development of PALI-2108 towards our first-in-human study, which is on track to start later this year. We are committed to advancing our pioneering research initiatives aimed at improving the lives of patients suffering from UC and other inflammatory conditions.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (PALI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.